Search results for " tricuspid valve"

showing 3 items of 3 documents

12‐Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation

2021

Objectives We investigated the durability of tricuspid regurgitation (TR) reduction and the clinical outcomes through 12 months after transcatheter tricuspid valve repair (TTVr) with the PASCAL Transcatheter Valve Repair System. Background TTVr has rapidly developed and demonstrated favorable acute outcomes, but longer follow-up data are needed. Methods Overall, 30 patients (age 77 ± 6 years; 57% female) received PASCAL implantation from September 2017 to May 2019 and completed a clinical follow-up at 12 months. Results The TR etiology was functional in 25 patients (83%), degenerative in three (10%), and mixed in two (7%). All patients had TR severe or greater (massive or torrential in 80%)…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)030204 cardiovascular system & hematologytranscatheter tricuspid valve intervention PASCAL 12-month outcomes severe tricuspid regurgitation right-sided heart failure03 medical and health sciences0302 clinical medicinemedicineHumansEndocarditisRadiology Nuclear Medicine and imagingddc:610030212 general & internal medicineTRICUSPID VALVE REPAIRStrokeSurvival rateAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industryPascal (unit)General Medicinemedicine.diseaseTricuspid Valve InsufficiencySurgeryTreatment OutcomeHeart failureEtiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Interventions
researchProduct

Focus on the unique mechanisms involved in thoracic aortic aneurysm formation in bicuspid aortic valve versus tricuspid aortic valve patients: clinic…

2013

OBJECTIVES: The involvement of different factors in the onset of thoracic aortic aneurysm (TAA) in patients with a bicuspid aortic valve (BAV) vs those with a tricuspid aortic valve (TAV) is well recognized. However, the molecular, genetic and cellular mechanisms driving TAA remain unclear. The aim of this study was to identify the different mechanisms involved in TAA development in patients with BAV vs TAV. METHODS: Aorta specimens and DNA samples were collected from 24 BAV (18 men and 6 women; mean age: 54.2 ± 14.39 years) and 110 TAV (79 men and 31 women, mean age: 66 ± 9.8 years) patients. A control group of 128 subjects (61 men and 67 woman, mean age: 61.1 ± 5.8 years) was also enrolle…

Aortic valveMaleThoracicHeart Valve DiseasesApoptosisPilot ProjectsBicuspid aortic valve; Clinical implications; Identifying different genetic and histological profiles; Thoracic aortic aneurysm; Tricuspid aortic valve; Adult; Aged; Aortic Aneurysm Thoracic; Aortic Valve; Apoptosis; Comorbidity; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heart Valve Diseases; Histocytochemistry; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Pilot Projects; Polymorphism Single Nucleotide; Risk Factors; Tricuspid ValveComorbidityBicuspid aortic valveBicuspid Aortic Valve DiseaseGene FrequencyFibrosisRisk FactorsClinical implicationsTricuspid valvebiologyHistocytochemistryGeneral MedicineSingle NucleotideMiddle AgedAortic Aneurysmmedicine.anatomical_structureMatrix Metalloproteinase 9Aortic ValveCardiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicinePulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBicuspid aortic valveGenotypeThoracic aortic aneurysmTricuspid aortic valvePolymorphism Single Nucleotidemedicine.arteryInternal medicineThoracic aortic aneurysmAscending aortamedicineSettore MED/05 - Patologia ClinicaHumansGenetic Predisposition to DiseasePolymorphismIdentifying different genetic and histological profilesAgedAortaAortic Aneurysm Thoracicbusiness.industryAngiotensin-converting enzymeSettore MED/23 - Chirurgia Cardiacamedicine.diseasebiology.proteinSurgerybusinessEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

First-in-Human Percutaneous Circumferential Annuloplasty for Secondary Tricuspid Regurgitation

2020

Transcatheter therapies to treat tricuspid regurgitation are being developed, but few have attempted the gold standard of surgical repair: ring annuloplasty. We describe the first-ever fully percutaneous implantation of a circumferential, semirigid annuloplasty ring to treat massive secondary tricuspid regurgitation. (Level of Difficulty: Advanced.)

0301 basic medicinemedicine.medical_specialtyPercutaneousRDS ring delivery systemTR tricuspid regurgitationCase ReportRegurgitation (circulation)030105 genetics & heredityelectrocardiogramright ventricletricuspid valve03 medical and health sciences0302 clinical medicineClinical CaseTR - Tricuspid regurgitationmedicineDiseases of the circulatory (Cardiovascular) systemTVA tricuspid valve annuluscardiovascular diseasesSurgical repairTricuspid valvetreatmentbusiness.industryRing annuloplasty3-dimensionalTEE transesophageal echocardiographyGold standard (test)First in humanvalve repairCT computed tomographySurgerymedicine.anatomical_structureTTE transthoracic echocardiographyRC666-701cardiovascular systemTV tricuspid valveCardiology and Cardiovascular MedicinebusinessRCA right coronary artery030217 neurology & neurosurgeryJACC: Case Reports
researchProduct